David Lebowitz
Stock Analyst at Citigroup
(4.31)
# 380
Out of 5,150 analysts
119
Total ratings
59.77%
Success rate
14.26%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $79.45 | +5.73% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $62.27 | +34.90% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $29.54 | +62.49% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $13.12 | +52.44% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $241.38 | +20.14% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $98.86 | +4.19% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.14 | +18.23% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $37.02 | -40.57% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $66.54 | +0.69% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $41.69 | +34.32% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.82 | -27.64% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.29 | +16.28% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $64.29 | -30.00% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $93.04 | -26.91% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $434.80 | -12.14% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $60.43 | +58.86% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $5.17 | +132.11% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $327.30 | -49.89% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $24.12 | +61.69% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.62 | -2.87% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $9.15 | +4,326.23% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.74 | +274.33% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $79.45
Upside: +5.73%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $62.27
Upside: +34.90%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $29.54
Upside: +62.49%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $13.12
Upside: +52.44%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $241.38
Upside: +20.14%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $98.86
Upside: +4.19%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.14
Upside: +18.23%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $37.02
Upside: -40.57%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $66.54
Upside: +0.69%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $41.69
Upside: +34.32%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.82
Upside: -27.64%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.29
Upside: +16.28%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $64.29
Upside: -30.00%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $93.04
Upside: -26.91%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $434.80
Upside: -12.14%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $60.43
Upside: +58.86%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $5.17
Upside: +132.11%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $327.30
Upside: -49.89%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $24.12
Upside: +61.69%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.62
Upside: -2.87%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $9.15
Upside: +4,326.23%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.74
Upside: +274.33%